Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: A randomized controlled trial

Pediatric Infectious Disease Journal

Volumn 19, Issue 5, 2000, Pages 410-417

  Hedrick, James A ^a   Barzilai, Asher ^b   Behre, Ulrich ^c   Henderson, Frederick W ^d   Hammond, Janet ^e   Reilly, Lucy ^f   Keene, Oliver ^f  

^a Kentucky Pediatric Research Institute   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

^c Private Practice   (Germany)

^d N Carolina Children Young Adults C   (United States)

^e GLAXOSMITHKLINE   (United States)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Influenza; Neuraminidase inhibitor; Pediatrics; Relenza; Treatment; Zanamivir

Indexed keywords

ZANAMIVIR;

ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0034078730     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200005000-00005     Document Type: Article

References (26)

1. Glezen WP. Consideration of the risk of influenza in children and indications for prophylaxis. Rev Infect Dis 1980;2:408-20.
2. Fox JP, Hall CE, Cooney MK, Foy HM. Influenza virus infections in Seattle families, 1975-1979: I. Study design, methods and the occurrence of infections by time and age. Am J Epidemiol 1982;116:212-27.
3. Taber LH, Paredes A, Glezen WP, Couch RB. Infection with influenza A/Victoria virus in Houston families, 1976. J Hyg Camb 1981;86:303-13.
4. Glezen WP, Cherry JD. Influenza viruses. In: Feigin RD, Cherry JD, eds. Textbook of pediatric infectious diseases. 3rd ed. Philadelphia: Saunders, 1992:1688-704.
5. Frank AL, Taber LH, Wells CR, Wells JM, Glezen WP, Paredes A. Patterns of shedding of myxoviruses and paramyxoviruses in children. J Infect Dis 1981;144:433-41.
6. Hall CB, Douglas RG, Geiman JM, Meagher MP. Viral shedding patterns of children with influenza B infection. J Infect Dis 1979;140:610-13.
7. Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 1997;337: 874-80.
8. The MIST Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998;352:1877-81.
9. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999;180: 254-61.
10. Monto AS, Robinson DP, Herlocher ML, Hinson JM, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999; 282:31-5.
11. Ellis JS, Fleming DM, Zambon MC. Multiplex reverse transcription PCR for surveillance of influenza A and B viruses in England and Wales in 1995 and 1996. J Clin Microbiol 1997;35:2076-82.
12. Hirst GC. The quantitative determination of influenza virus and antibodies by means of red cell agglutination. J Exp Med 1942;75:47-64.
13. Barnett JM, Cadman A, Gor D, et al. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during Phase II clinical efficacy studies. Antimicrob Agents Chemother 2000;44:78-87.
14. Noether GE. Sample size determination for some common nonparametric tests. J Am Stat Assoc 1987;82:645-7.
15. Lehman EL. Nonparametrics: statistical methods based on ranks. San Francisco: Holden-Day, 1975.
16. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman & Hall, 1993.
17. Koch GG, Edwards S. Clinical efficacy trials with categorical data. In: Peace KE, ed. Biopharmaceutical statistics for drug development. New York: Dekker, 1988:403-57.
18. Gubareva LV, Mastrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998;178:1257-62.
19. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996; 275:295-9.
20. Keech M, Scott AJ, Ryan PJJ. The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med 1998;48:85-90.
21. Cass LMR, Browne J, Pickford M, et al. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet 1999;36:21-31.
22. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997; 46(RR-9):1-26.
23. Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 1992;176:119-30.
24. Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 1991;35:1741-7.
25. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989; 321:1696-702.
26. Hall CB, Dolin R, Gala CL, et al. Children with influenza A infection: treatment with rimantadine. Pediatrics 1987;80: 275-82.